| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 0.21 | 23.5% |
| Total Income | 0.21 | 23.5% |
| Expenditure | 10.43 | 1.6% |
| PBT | — | |
| Net Profit | -12.69 | 75.0% |
| OPM | — | |
| NPM | — | |
| EPS | -0.54 | 64.0% |
BioXcel Therapeutics Reports Q1 2026 Financial Results
15 May 2026 · 15 May, 4:41 pm
Summary
BioXcel Therapeutics reported its financial results for the first quarter of 2026. Net revenue from IGALMI® was $206,000, an increase from $168,000 in the same period of 2025. The company's net loss was $12.7 million, compared to a net loss of $7.3 million for the same period in the previous year. The FDA accepted the sNDA for IGALMI® for at-home use, with a PDUFA target action date of November 14, 2026. The company is also evaluating strategic options to maximize shareholder value.
Key Highlights
- 1
BioXcel Therapeutics reported net revenue from IGALMI® of $206,000 for the first quarter of 2026, compared to $168,000 for the same period in 2025.
- 2
Research and Development expenses decreased to $3.0 million for the first quarter of 2026, compared to $4.6 million for the same period in 2025.
- 3
Selling, General and Administrative expenses increased to $7.2 million for the first quarter of 2026, compared to $5.7 million for the same period in 2025.
- 4
The company reported a net loss of $12.7 million for the first quarter of 2026, compared to a net loss of $7.3 million for the same period in 2025.
- 5
Cash and cash equivalents and restricted cash totaled $17.2 million as of March 31, 2026.
- 6
The FDA accepted the sNDA for IGALMI® use in the at-home (outpatient) setting, setting November 14, 2026, as the PDUFA date.
Management Comments
Vimal Mehta
Ph.D.
“The first quarter was marked by tremendous progress, achieving a major regulatory milestone and developing the IGALMI commercial launch plan for the at-home setting. “We are very pleased with the recent approval of another product in Alzheimer’s agitation, in an area adjacent to our focus on the acute treatment of agitation in Alzheimer’s dementia with BXCL501. Our first-in-class mechanism has the potential to make a transformative impact on the lives of a large patient population in this disease area. We are actively pursuing strategic options to maximize shareholder value for the IGALMI franchise.”
Informational and educational content only. Not investment advice.